Glaukos Corporation

NYSE:GKOS

Sector

🏥 Health Care

Industries

🕶 Eyewear

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 5.72 B

Share Price

USD 96.80

Avg Daily Volume

1,025,485

Change (1 day)

-3.35%

Change (1 year)

-14.35%

Change (YTD)

-35.44%

Glaukos Corporation Market Capitalization on June 23, 2025: USD 5.72 B

Glaukos Corporation Market Capitalization is USD 5.72 B on June 23, 2025, a 1.98% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Glaukos Corporation 52-week low Market Capitalization is USD 9.13 B on June 23, 2025, which is 59.54% above the current Market Capitalization.
Glaukos Corporation 52-week low Market Capitalization is USD 4.61 B on June 23, 2025, which is -19.38% below the current Market Capitalization.
Glaukos Corporation average Market Capitalization for the last 52 weeks is USD 6.64 B.

Daily

From:

To:

Zoom:

Key data

Date	Market Capitalization	Share Price	Share Price	Price to Earnings Ratio (P/E)

NYSE: GKOS

Glaukos Corporation

CEO	Mr. Thomas William Burns
IPO Date	June 25, 2015
Location	United States
Headquarters	229 Avenida Fabricante
Employees	995
Sector	🏥 Health Care
Industries Eyewear 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.